Houston health tech company bounces back from COVID-19 in a big way

HOUSTON INNOVATORS PODCAST EPISODE 82

Kevin Coker, CEO of Proxima Clinical Research, say his company transform from uncertainty to almost uncontrollable growth in just 12 months. He shares what happened on this week's episode of the Houston Innovators Podcast. Photo courtesy of Proxima

The pandemic hit life science innovation hard. And no one knows that better than Kevin Coker, co-founder and CEO of Proxima Clinical Research, a Houston-based contract research organization focused on supporting life science startups as they grow and scale.

"Last year from January to June, it was very tough," Coker says on this week's episode of the Houston Innovators Podcast. "Hospitals shut down, so any existing projects we had ongoing just halted."

Coker and his team of 12 — including co-founder and chairman, Larry Lawson — at the time didn't have any new projects coming in and were at the mercy of the pandemic.

"Everything was flat. In May, I was starting to worry. I didn't know how long we were going to have to weather the storm," Coker remembers.

Then, in June, things started changing, he says. As hospitals started to reopen and clinical research was reignited. Initially, some COVID diagnostic products were gaining momentum, as well as some emergency use authorization products.

"Things just really started taking off for us," Coker says. "I think it was really a product of investors and people being able to make decisions despite the pandemic."

Coker describes the experience not as a rollercoaster — it was all downhill for Proxima and then business took flight. Last quarter, the company was signing a new contract every two to three days. With the influx of projects, Coker says his team scaled to 50 full time employees and 75 part time team members — most of these new additions Coker hasn't even met yet, since the staff has been working remotely.

"We're a good barometer for what's happening not only locally but across the country," Coker says. "As Proxima has grown, it's really show how the Houston life science market is growing."

Now, Coker is focused on maintaining the company culture at Proxima as well as finding a new, larger office space in the Texas Medical Center — Proxima's current office is in the TMC Innovation Institute.

Coker says it's his intention to keep its operations smaller and more hands on than the usual CRO, which typically has 5,000 to 10,000 employees and multi-billion dollars in revenue, and focused on startups and small companies.

"That type of organization doesn't work well with a small med device or pharmaceutical company. We wanted to create a company that looked and felt like the startups," he says.

Coker shares more about Proxima's growth and Houston's potential of being a major life science hub on the episode. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Austin company to bring AI-powered school to The Woodlands

AI education

Austin-based Alpha School, which operates AI-powered private schools, is opening its first Houston-area location in The Woodlands.

The 8,000-square-foot school, scheduled to be ready for the 2026-27 academic year, initially will serve students in kindergarten through eighth grade. Alpha says the school will offer “open workshop spaces and innovative classrooms that support personalized instruction, core academics, leadership development, and real-world life skills.”

Alpha sets aside two hours each school day for the AI-driven, self-paced study of core subjects like math, reading and science. The rest of each school day consists of life-skills workshops focusing on topics such as leadership and financial literacy.

Alpha’s school in The Woodlands has begun accepting applications for the 2026-27 school year. Annual tuition costs $40,000.

“The Woodlands is one of the most dynamic, forward-thinking communities in Texas, and Alpha is proud to bring

an innovative educational model that complements its strong academic foundation,” says Rachel Goodlad, head

of expansion for Alpha.

Founded in 2014, Alpha School combines adaptive technology-driven instruction with immersive life-skills workshops. Its model emphasizes mastery-based learning in core subjects alongside development of communication, critical thinking, financial literacy and leadership skills. It operates more than 15 schools across the country.

Elsewhere in Texas, Alpha operates schools in Austin, Brownsville, Fort Worth and Plano. Alpha also operates 12 Texas Sports Academy campuses in Texas, including locations in Houston, Pearland and Richmond, along with a NextGen Academy esports school in Austin, a school for gifted students in Georgetown, and lower-cost Nova Academy campuses in Austin and Bastrop.

Alpha has fans and critics. While supporters tout students’ high achievement rates, detractors complain about the high tuition and the AI-influenced depersonalization of education.

“Students and our country need to be in relationship with other human beings,” Randi Weingarten, president of the American Federation of Teachers, a teachers union, tells The New York Times. “When you have a school that is strictly AI, it is violating that core precept of the human endeavor and of education.”

Alpha co-founder MacKenzie Price, a podcaster and social media influencer, doesn’t share Weingarten’s views.

“Parents and teachers: We need to embrace this change,” Price wrote after President Trump signed an executive order promoting AI in schools.

The Times notes that Alpha doesn’t employ AI as a tutor or a supplement. Rather, the newspaper says, AI is “the school’s primary educational driver to move students through academic content.”

Houston space tech co. lands $175M and more innovation news to know

Trending News

Editor's note: The top Houston innovation news for the month includes major fundraising rounds for two Houston scaleups and local inductees into the National Academy of Inventors. Here are the five most-read InnovationMap headlines from March 1-15, 2026:

1. Intuitive Machines secures $175M equity investment to fuel growth

Intuitive Machines has landed a $175 million investment as it looks secure satellite deals and develop space-based data centers. Photo courtesy Intuitive Machines.

Houston-based space infrastructure and services company Intuitive Machines has secured a $175 million equity investment from unidentified institutional investors. The investors received shares of Class A stock in exchange for their funding. Publicly held Intuitive Machines (Nasdaq: LUNR) says it plans to use the capital to help build revenue and invest in technology, including communications and data-processing networks. Continue reading.

2. Houston e-commerce giant Cart.com raises $180M, surpasses $1B in funding

Cart.com has raised $180 million to scale its logistics network, expand AI capabilities and develop workflow automation tools. Photo courtesy of Cart.com

Houston-based commerce and logistics platform Cart.com has raised $180 million in growth capital from private equity firm Springcoast Partners, pushing the startup past the $1 billion funding mark since its founding in 2020. Cart.com says it will use the capital to scale its logistics network, expand AI capabilities and develop workflow automation tools. Continue reading.

3. Houston leads Texas with 7 new National Academy of Inventors senior members

The University of Houston has more faculty named to this year’s senior member class of the National Academy of Inventors than any other Texas institution. Photos courtesy UH.

The University of Houston is now home to seven new senior members of the National Academy of Inventors. According to UH, its seven new members represent the largest group from any single Texas institution this year, bringing the university's total senior member count to 46. Continue reading.

4. Booming Houston suburb launches innovation grant to attract startups

The City of Sugar Land is putting money on the table to support startups that relocate jobs to southwest Houston. Photo via Getty Images.

Think you’ve got a burgeoning startup? Consider moving it to southwest Houston. The City of Sugar Land announced the Sugar Land Starts Innovation Fund to support companies that move jobs to the area. Continue reading.

5. 6+ can't-miss Houston business and innovation events in March

From CERAWeek to H-Town Roundup, here's what not to miss this month and how to register. Photo courtesy of CERAWeek

March brings the return of some of Houston’s signature innovation events, plus insightful talks and celebrations in honor of Women's History Month. Here’s what not to miss and how to register. Continue reading.

Houston researcher secures $1.7M to develop drug for aggressive form of breast cancer

cancer research

A University of Houston researcher has joined a $3.2 million effort to develop a new drug designed to attack a cancer-driving protein commonly found in triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is one of the most difficult-to-treat forms of cancer and accounts for 10 percent to 15 percent of all breast cancer cases. The disease gets its name because tumors associated with it test negative for estrogen receptors, progesterone receptors and excess HER2 protein, making it difficult to target. Due to this, TNBC is often treated with general chemotherapy, which can come with negative side effects and drug resistance, according to UH.

UH College of Pharmacy research associate professor Wei Wang is developing a drug that can target the disease more specifically. The drug will target MDM2, a protein often overproduced in TNBC that also contributes to faster tumor growth.

Wang is working on a team led by Wei Li, director of the University of Tennessee Health Science Center College of Pharmacy’s Drug Discovery Center. She has received $1.7 million to support the research.

Wang and UH professor of pharmacology and toxicology Ruiwen Zhang have discovered a compound that can break down MDM2. In early laboratory models, the compound has shown the ability to shrink tumors.

Wang and Zhang will focus on understanding how the treatment works and monitoring its effectiveness in models that closely mirror human disease.

“We will study how the drug targets MDM2 and evaluate the most promising drug candidates to determine effective dosing, understand how the drug behaves in the body, compare it with existing treatments and assess early safety,” Wang said in a news release.

Li’s team at the University of Tennessee will be working on the chemistry and drug design end of the project.

“This work could lead to an entirely new class of therapies for triple-negative breast cancer,” Li added in the release. “We’re hopeful that by directly removing the MDM2 protein from cancer cells, we can help more patients respond to treatment regardless of their tumor type.”

View All Listings